Notably, the expression of the CD81 molecule on both tumor-infiltrating CD8+ and CD4+ T cells was significantly enhanced following GCP combination therapy, emphasizing the potential role of CD81 in T-cell reactivation. The gene discussed is CD81; the disease is neoplasm.